Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
Phase 2/3
Active, not recruiting
NCT04655976
| Condition | Lung Cancer, Non-Small Cell |
|---|
| Phase | Phase 2/3 |
|---|
| Sponsor | GlaxoSmithKline |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 758 participants |
|---|
| Interventions | Cobolimab, Dostarlimab, Docetaxel |
|---|
| Start date | Dec 8, 2020 |
|---|
| Completion date | Jun 5, 2025 |
|---|
| Results posted | Jul 1, 2026 |
|---|
Summary
This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.
Overall Survival (OS) (Arm A Versus Arm C)
Up to approximately 234 weeks · Months
| Cobolimab + Dostarlimab + Docetaxel (Arm A) | 11.9 Months |
|---|
| Docetaxel (Arm C) | 11.3 Months |
|---|
| p-value | 0.079708 |
|---|
| Hazard Ratio (HR) | 0.85 (95% CI 0.68–1.06) |
|---|
Overall Survival (OS) (Arm B Versus Arm C)
Up to approximately 234 weeks · Months
| Dostarlimab + Docetaxel (Arm B) | 11.8 Months |
|---|
| Docetaxel (Arm C) | 11.3 Months |
|---|
| p-value | 0.369509 |
|---|
| Hazard Ratio (HR) | 0.96 (95% CI 0.77–1.20) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.